Himension Capital (Singapore)’s CRISPR Therapeutics CRSP Stock Holding History

Himension Capital (Singapore)’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.58M	Sell	83,897 -8,584	-9%	-$452K	0.28%	36
2026 Q1	$4.4M	Buy	92,481 +8,091	+10%	+$427K	0.34%	36
2025 Q4	$4.43M	Buy	84,390 +12,051	+17%	+$722K	0.27%	35
2025 Q3	$4.69M	Sell	72,339 -10,781	-13%	-$619K	0.29%	32
2025 Q2	$4.04M	Sell	83,120 -10,454	-11%	-$405K	0.32%	29
2025 Q1	$3.18M	Buy	93,574 +12,804	+16%	+$543K	0.27%	33
2024 Q4	$3.18M	Sell	80,770 -375	-0.5%	-$17.7K	0.22%	31
2024 Q3	$3.81M	Buy	81,145 +3,603	+5%	+$183K	0.3%	20
2024 Q2	$4.19M	Buy	77,542 +8,527	+12%	+$493K	0.3%	22
2024 Q1	$4.7M	Hold	69,015	–	–	0.35%	23
2023 Q4	$4.32M	Buy	+69,015	New	+$3.82M	0.39%	19
2021 Q4	–	Sell	-188,634	Closed	-$21.1M	–	16
2021 Q3	$21.1M	Buy	188,634 +31,300	+20%	+$3.93M	1.65%	13
2021 Q2	$25.5M	Buy	+157,334	New	+$19.1M	2.47%	10

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Himension Capital (Singapore)'s CRSP Position: Q2 2026 in Review

Himension Capital (Singapore) reduced its CRISPR Therapeutics (CRSP) stake by 9.3% in Q2 2026, selling an estimated $452K and leaving 83,897 shares worth $4.58M. The position accounts for 0.28% of the portfolio, ranked #36.

Himension Capital (Singapore) first reported a position in CRSP in Q2 2021 and has held it in 13 quarters since. The position peaked at $25.5M in Q2 2021. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Himension Capital (Singapore) held 83,897 shares of CRISPR Therapeutics worth $4.58M as of Q2 2026.
Himension Capital (Singapore) sold 8,584 CRISPR Therapeutics shares in Q2 2026, an estimated $452K.
CRISPR Therapeutics made up 0.28% of Himension Capital (Singapore)'s portfolio in Q2 2026, its #36 holding.
Himension Capital (Singapore) first reported a position in CRISPR Therapeutics in Q2 2021 and has held it in 13 quarters since.
Himension Capital (Singapore)'s CRISPR Therapeutics position peaked at $25.5M in Q2 2021.
523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Himension Capital (Singapore)'s 13F filing for Q2 2026, filed 13 Aug 2026.